Then COVID-19 hit
Although originally developed for type 2 diabetes, Mounjaro has shown impressive results in supporting weight loss, particularly when compared to other medications in the same class such as Wegovy and Ozempic, which act only on GLP-1
Novel dual-GLP-1/GIP receptor agonists that have been developed to treat diabetes (Salameh et al., 2020
Preclinical studies in rodents with long-acting GIP, GLP-1, and GLP-2 analogues, alongside related clinical trials, suggest these molecules are safe, and furthermore, may improve overall bone health
Protective effects of intra-articular formulated liraglutide in osteoarthritis: preclinical studies
The end result, better blood sugar control, looks similar on paper but arrives through entirely different routes